Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihexazin
- Development stage
- Unknown
- Lead developer
- Laboratorios Juste
- Modality
- Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Dihexazin is a small molecule active pharmaceutical ingredient (API) developed and manufactured by Laboratorios Juste (Grupo Juste), a Spanish pharmaceutical company specializing in radiology and contrast media. It is classified as a contrast media agent intended for use in diagnostic imaging applications. The compound has a molecular formula of C50H52N3O6P and a molecular weight of approximately 821.94. As an API in Grupo Juste's portfolio, it is part of their established line of specialty chemicals for the diagnostic imaging market. While its specific clinical applications and detailed mechanism of action are not widely publicized, it is listed as an approved product within the company's chemical and pharmaceutical ingredient offerings.
- Brand names
- Dihexazin
- Other names
- CAS 2182626-95-3CAS2182626-95-3CAS-2182626-95-3
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)M1 (Muscarinic acetylcholine receptor M1)SPHK2 (Sphingosine kinase 2)
Beyond the preview
Go deeper on dihexazin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihexazin.